Xeris Biopharma Holdings Inc banner

Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 6.055 USD -0.25% Market Closed
Market Cap: $1B

Wall Street
Price Targets

XERS Price Targets Summary
Xeris Biopharma Holdings Inc

Wall Street analysts forecast XERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XERS is 11.366 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.

Lowest
Price Target
8.08 USD
33% Upside
Average
Price Target
11.366 USD
88% Upside
Highest
Price Target
18.9 USD
212% Upside
Xeris Biopharma Holdings Inc Competitors:
Price Targets

Revenue
Forecast

100% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
100% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

For the last 7 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 100%. The projected CAGR for the next 4 years is 26%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XERS's stock price target?
Price Target
11.366 USD

According to Wall Street analysts, the average 1-year price target for XERS is 11.366 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.

What is Xeris Biopharma Holdings Inc's Revenue forecast?
Projected CAGR
26%

For the last 7 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 100%. The projected CAGR for the next 4 years is 26%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett